Mihael Polymeropoulos, Vanda Pharmaceuticals CEO
September 19, 2022 11:44 AM EDT
Pharma
Law

Van­da inks $11.5M deal to set­tle off-la­bel drug pro­mo­tion ac­cu­sa­tions

Nicole DeFeudis

Editor

Van­da Phar­ma­ceu­ti­cals took the FDA to court three sep­a­rate times this year as it strug­gles to win over reg­u­la­tors with its sleep and chron­ic di­ges­tive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times